North America In-Vitro Diagnostics Market Forecast to 2030
North America In-Vitro Diagnostics Market Forecast to 2030 – Regional Analysis – by Product & Services (Reagents & Kits, Instruments, and Software & Services), Technology (Immunoassay/ Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Blood Glucose Self-Monitoring, Coagulation & Hemostasis, Hematology, Urinalysis, and Others), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Autoimmune Diseases, Nephrology, and Others), and End User (Hospitals, Laboratories, Homecare, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic Fuels North America In-Vitro Diagnostics Market
Point-of-care testing (POCT) is a pivotal opportunity in the in vitro diagnostics market, revolutionizing healthcare delivery with its potable and rapid diagnostic capabilities. These tests, conducted at or near the patient’s location, offer immediate results, enabling timely clinical decision-making. Several factors drive the growth of POCT.
Firstly, the demand for convenient and swift diagnostic solutions in healthcare settings, such as emergency rooms, clinics, and home care, propels the expansion of POCT. Secondly, technological advancements have led to the development of compact and user-friendly POCT devices.
Moreover, the COVID-19 pandemic underscored the significance of rapid and accessible diagnostics. The pandemic accelerated the deployment and utilization of point-of-care COVID-19 tests, showcasing the relevance and potential of POCT in managing infectious diseases on a global scale. This experience accelerated research and development on POCT, further driving innovation and investment in portable testing solutions.
IVDs that are used in the diagnosis of infectious diseases include immunoassays, and molecular assays. Diagnostics companies also focus on making rapid advancements in their offerings to manage COVID-19. Further, regulatory authorities introduced temporary amendments or modifications to their standards, which favored the launches of new IVDs during the pandemic. The demand for molecular diagnostics and immunoassays surged due to these government initiatives. Thus, the COVID-19 pandemic has benefitted the in-vitro diagnostics market due to the rising demand for point-of-care (POC) diagnostics and laboratory testing procedures.
North America In-Vitro Diagnostics Market Overview
North America region includes the US, Canada, and Mexico. It holds the largest share of the in-vitro diagnostics market by geography. All three countries in the region are witnessing considerable demand for in-vitro diagnostics. Certain factors, such as the increasing prevalence of chronic & infectious diseases, focus on efficient disease diagnosis, and a higher need for advanced healthcare systems are boosting the adoption of in-vitro diagnostics in the region. The US held the largest share of the North America in-vitro diagnostics market. Chronic diseases such as cancer and cardiovascular diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country have at least one chronic disease. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~18.2 million adults aged 20 and above had coronary artery disease (CAD) in the US. Heart disease is the leading cause of death among people in the country. Additionally, the American Hospital Association estimates ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. The high incidence of chronic diseases results in a huge demand for diagnostic procedures, which, in turn, drives the in-vitro diagnostics market in the US. Growing emphasis on preventive care coupled with enhanced access to healthcare facilities would further boost the market growth in the coming years.
With the exponentially rising need for in-vitro diagnostics tools with the growing patient pool, the market players focus on developing advanced diagnostic systems enabling rapid examinations. For instance, in February 2019, Grail, a US-based player in diagnostic services, received financial aid of US$ 1.5 billion from Microsoft and Amazon with an aim to develop new technologies for rapid cancer detection. Additionally, extensive technological advancements due to developed healthcare infrastructure and rising expenditure are generating lucrative opportunities for the growth of the in-vitro diagnostics market in the country. For instance, in July 2019, Sysmex America, Inc., one of the prominent players in the in-vitro diagnostics market, showcased its new integrated in-vitro diagnostic machine named PS-10 at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo organized in Anaheim, California. The machine is designed to perform complex laboratory tests, routine cytometry, and hematology assessments. Similarly, in May 2020, Bio-Rad Laboratories Inc. received Emergency Use Authorization (EUA) for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit from the US Food and Drug Administration (FDA). The SARS-CoV-2 ddPCR test runs on Bio-Rad’s QX200 and QXDx ddPCR systems.
North America In-Vitro Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
North America In-Vitro Diagnostics Market Segmentation
The North America in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.
Based on product & services, the North America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the North America in-vitro diagnostics market in 2022.
Based on technology, the North America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the North America in-vitro diagnostics market in 2022.
Based on application, the North America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the North America in-vitro diagnostics market in 2022.
Based on end user, the North America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held the largest share of the North America in-vitro diagnostics market in 2022.
Based on country, the North America in-vitro diagnostics market is segmented int o the US, Canada, and Mexico. The US dominated the North America in-vitro diagnostics market in 2022.
Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America in-vitro diagnostics market.
Summary Info
Industry: | |
---|---|
Pricing options: | |
Geographical coverage: | |
Year of Publication: |
According to The Research Team’ research, the North America in-vitro diagnostics market was valued at US$ 21,207.07 million in 2022 and is expected to reach US$ 33,183.41 million by 2030, registering a CAGR of 5.8% from 2022 to 2030. Surge in demand for IVD during Covid-19 pandemic and increasing demand for personalized medicine and genomics are among the critical factors attributed to the North America in-vitro diagnostics market expansion.
North America is at the forefront of personalized medicine and genomics research. There is increasing integration of genomics and molecular diagnostics into routine patient care. Companies are involved in developing advanced genetics hold substantial opportunities for the in-vitro diagnostics market. North America, particularly the US and Canada, has been a hub for genomic research centers that contribute notably to understanding and knowledge on the genetic basis of diseases, identification of biomarkers, and development of targeted therapies. Both these countries have launched precision medicine initiatives to integrate genomics into clinical practices. North America has been a leader in cancer genomics, hosting extensive research and clinical trials focused on understanding the genetic factors associated with different types of cancer. These trials aim to evaluate the efficacy of targeted therapies, immunotherapies, and other innovative treatments based on the genetic characteristics of patients’ tumors. The American Cancer Society estimates that the US would record 1.9 million new cancer cases (~5,370 cases per day) and 609,820 deaths from cancer in 2023. With such a high incidence, there is a pressing need for effective treatment to improve the quality of life of these patients.
Personalized medicine involves running in-vitro diagnostics tests on patients to stratify them into subgroups based on their unique characteristics. The field of personalized medicine, along with advancements in genomics sequencing, molecular profiling, and other diagnostic technologies, has the potential to revolutionize healthcare by providing targeted, precise, and individualized treatment approaches. Genetics has become increasingly accessible globally. Thus, the demand for personalized medicine and genomics will propel the growth of the in-vitro diagnostics market during the forecast period.
On the contrary, cumbersome reimbursement procedures and stringent regulations regarding products hamper the North America in-vitro diagnostics market.
Based on product & services, the North America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held 78.7% share of North America in-vitro diagnostics market in 2022, amassing US$ 16,697.92 million. It is projected to garner US$ 26,392.04 million by 2030 to expand at 5.9% CAGR during 2022–2030.
Based on technology, the North America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held 27.9% share of North America in-vitro diagnostics market in 2022, amassing US$ 5,906.50 million. It is projected to garner US$ 9,629.30 million by 2030 to expand at 6.3% CAGR during 2022–2030.
Based on application, the North America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held 39.4% share of North America in-vitro diagnostics market in 2022, amassing US$ 8,362.74 million. It is projected to garner US$ 13,330.05 million by 2030 to expand at 6.0% CAGR during 2022–2030.
Based on end user, the North America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held 49.4% share of North America in-vitro diagnostics market in 2022, amassing US$ 10,476.75 million. It is projected to garner US$ 15,971.49 million by 2030 to expand at 5.4% CAGR during 2022–2030.
Based on country, the North America in-vitro diagnostics market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.2% share of North America in-vitro diagnostics market in 2022. It was assessed at US$ 18,077.33 million in 2022 and is likely to hit US$ 28,474.68 million by 2030, exhibiting a CAGR of 5.8% during 2022–2030.
Key players operating in the North America in-vitro diagnostics market are Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America In-Vitro Diagnostics Market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America In-Vitro Diagnostics Market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America In-Vitro Diagnostics Market – Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Increasing Prevalence of Chronic and Infectious Diseases
4.1.2 Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic
4.2 Market Restraint
4.2.1 Insufficiency of Regulatory Frameworks and Reimbursement Policies
4.3 Market Opportunities
4.3.1 Integration of IVD with Digital Health Technologies
4.4 Future Trends
4.4.1 Increasing Demand for Personalized Medicine and Genomics
5. In-Vitro Diagnostics Market – North America Market Analysis
5.1 North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2022 – 2030
6. North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 – by Product and Services
6.1 Overview
6.2 North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
6.3 Reagents and Kits
6.3.1 Overview
6.3.2 Reagents and Kits: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Software and Services
6.4.1 Overview
6.4.2 Software and Services: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Instruments
6.5.1 Overview
6.5.2 Instruments: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7. North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 – by Technology
7.1 Overview
7.2 North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
7.3 Immunoassay/ Immunochemistry
7.3.1 Overview
7.3.2 Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Clinical Chemistry
7.4.1 Overview
7.4.2 Clinical Chemistry: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Molecular Diagnostics
7.5.1 Overview
7.5.2 Molecular Diagnostics: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Microbiology
7.6.1 Overview
7.6.2 Microbiology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Blood Glucose Self-Monitoring
7.7.1 Overview
7.7.2 Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Coagulation and Hemostasis
7.8.1 Overview
7.8.2 Coagulation and Hemostasis: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Hematology
7.9.1 Overview
7.9.2 Hematology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Urinalysis
7.10.1 Overview
7.10.2 Urinalysis: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.11 Others
7.11.1 Overview
7.11.2 Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8. North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Infectious Disease
8.3.1 Overview
8.3.2 Infectious Diseases: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Diabetes
8.4.1 Overview
8.4.2 Diabetes: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Oncology
8.5.1 Overview
8.5.2 Oncology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Cardiology
8.6.1 Overview
8.6.2 Cardiology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Autoimmune Diseases
8.7.1 Overview
8.7.2 Autoimmune Diseases: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Nephrology
8.8.1 Overview
8.8.2 Nephrology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Others
8.9.1 Overview
8.9.2 Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9. North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Laboratories
9.4.1 Overview
9.4.2 Laboratories: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Homecare
9.5.1 Overview
9.5.2 Homecare: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10. North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 – Country Analysis
10.1 North America In-Vitro Diagnostics Market
10.1.1 Overview
10.1.2 North America In-Vitro Diagnostics Market, by Country
10.1.2.1 US: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 US: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.1.3 US: North America In-Vitro Diagnostics Market, by Product and Services, 2020–2030 (US$ Million)
10.1.2.1.4 US: North America In-Vitro Diagnostics Market, by Technology, 2020–2030 (US$ Million)
10.1.2.1.5 US: North America In-Vitro Diagnostics Market, by Application, 2020–2030 (US$ Million)
10.1.2.1.6 US: North America In-Vitro Diagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.2.2 Canada: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Canada: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.2.3 Canada: North America In-Vitro Diagnostics Market, by Product and Services, 2020–2030 (US$ Million)
10.1.2.2.4 Canada: North America In-Vitro Diagnostics Market, by Technology, 2020–2030 (US$ Million)
10.1.2.2.5 Canada: North America In-Vitro Diagnostics Market, by Application, 2020–2030 (US$ Million)
10.1.2.2.6 Canada: North America In-Vitro Diagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.2.3 Mexico: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 Mexico: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.2.3.3 Mexico: North America In-Vitro Diagnostics Market, by Product and Services, 2020–2030 (US$ Million)
10.1.2.3.4 Mexico: North America In-Vitro Diagnostics Market, by Technology, 2020–2030 (US$ Million)
10.1.2.3.5 Mexico: North America In-Vitro Diagnostics Market, by Application, 2020–2030 (US$ Million)
10.1.2.3.6 Mexico: North America In-Vitro Diagnostics Market, by End User, 2020–2030 (US$ Million)
11. Industry Landscape
11.1 Organic Developments
11.1.1 Overview
11.2 Inorganic Developments
11.2.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Danaher Corp
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Siemens AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sysmex Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Becton Dickinson and Co
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 bioMerieux SA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Bio-Rad Laboratories Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Qiagen NV
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America In-Vitro Diagnostics Market Segmentation
Table 2. US North America In-Vitro Diagnostics Market, by Product and Services – Revenue and Forecast to 2030 (US$ Million)
Table 3. US North America In-Vitro Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 4. US North America In-Vitro Diagnostics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. US North America In-Vitro Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada North America In-Vitro Diagnostics Market, by Product and Services – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada North America In-Vitro Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada North America In-Vitro Diagnostics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada North America In-Vitro Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 10. Mexico North America In-Vitro Diagnostics Market, by Product and Services – Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico North America In-Vitro Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico North America In-Vitro Diagnostics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico North America In-Vitro Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. Organic Developments Done by Companies
Table 15. Inorganic Developments Done by Companies
Table 16. Glossary of Terms, North America In-Vitro Diagnostics Market
LIST OF FIGURES
Figure 1. North America In-Vitro Diagnostics Market Segmentation, By Country
Figure 2. North America In-Vitro Diagnostics Market: Key Industry Dynamics
Figure 3. North America In-Vitro Diagnostics Market: Impact Analysis of Drivers and Restraints
Figure 4. North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2020 – 2030
Figure 5. North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
Figure 6. Reagents and Kits: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Software and Services: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Instruments: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 10. Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Clinical Chemistry: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Molecular Diagnostics: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Microbiology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Coagulation and Hemostasis: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Hematology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Urinalysis: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
Figure 20. Infectious Diseases: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Diabetes: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Oncology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Cardiology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Autoimmune Diseases: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Nephrology: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
Figure 28. Hospitals: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Laboratories: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Homecare: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Others: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. North America: North America In-Vitro Diagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. North America In-Vitro Diagnostics Market, by Country, 2022 & 2030 (%)
Figure 34. US: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Canada: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Mexico: North America In-Vitro Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
The List of Companies – North America In-Vitro Diagnostics Market
o Abbott Laboratories
o Becton Dickinson and Co
o bioMerieux SA
o Bio-Rad Laboratories Inc
o Danaher Corp
o F. Hoffmann-La Roche Ltd
o Qiagen NV
o Siemens AG
o Sysmex Corp
o Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.